Therapeutic Asset Ratings
119 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
ky-0118
Neoplasms
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
P1
C
(37)
Mdc-Car-Bcma001
Neoplasms
Technische Universität Dresden
P1
C
(37)
Pebezertinib
Neoplasms
Blueprint Medicines Corporation
P1
C
(37)
pf-07820435
Neoplasms
Pfizer
P1
C
(37)
pf-07826390
Neoplasms
Pfizer
P1
C
(37)
Remzistotug
Neoplasms
GlaxoSmithKline
P1
C
(37)
ro7673396
Neoplasms
Hoffmann-La Roche
P1
C
(37)
SAFIMALTIB
Neoplasms
Janssen Research & Development, LLC
P1
C
(37)
Tarlatamab
Neoplasms
GlaxoSmithKline
P1
C
(37)
Tnhyp217 Car T Cells
Neoplasms
National Cancer Institute (NCI)
P1
C
(37)
Idov-Safetm
Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early P1
C
(34)
SUMOYLATION INHIBITOR TAK-981
Neoplasms
Takeda
P1/2
D
(29)
[68ga]ga-oncoacp3
Neoplasms
Peking University First Hospital
N/A
D
(28)
68Ga-HTK03149
Neoplasms
British Columbia Cancer Agency
N/A
D
(28)
Oxodotreotide
Neoplasms
Sociedad Española de Medicina Nuclear e Imagen Molecular
D
(28)
68ga-sfb6-zn01
Neoplasms
Zhongnan Hospital
Early P1
NR
(0)
Lrk-4189 Escalation
Neoplasms
LARKSPUR BIOSCIENCES, INC.
P1/2
NR
(0)
Lrk-4189 Expansion
Neoplasms
LARKSPUR BIOSCIENCES, INC.
P1/2
NR
(0)
Lrk-4189 Optimization
Neoplasms
LARKSPUR BIOSCIENCES, INC.
P1/2
NR
(0)
Showing 101 to 119 of 119 assets
Previous
Page 5 of 5
Next
